Explore All 643 Venture Software Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | November 2, 2009 |
| Target | Aquafadas SAS |
| Sector | Software |
| Investor(s) | Omnes Capital |
| Deal Type | Venture |
FILTER BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2004 |
| PE ASSETS | 5.7B EUR |
| Size | Mega |
| Type | Sector Agnostic |
Omnes Capital formerly known as Credit Agricole Private Equity (CAPE) is the investment arm of financial services group Credit Agricole. Omnes Capital looks to invest in a range of investment stages and transaction types, including LBO/expansion, venture capital, mezzanine, renewable energy, co-investment, infrastructure, and special situations. The Firm's LBO/expansion group looks to invest €25 to €80 million to support growth initiatives and buyouts of small and mid-cap businesses operating in a variety of industries. Omnes Capital generally invests in businesses operating in France and Italy. Omnes Capital's mezzanine area was formed in 2002 and looks to provide €5 to €30 million of junior capital to similar sized established businesses. In addition to Omnes Capital's traditional equity and subordinated debt investment arm, the Firm also invests in infrastructure projects as well as provides capital for distressed businesses with €10 to €150 million in revenue. Omnes Capital was formed in 2004 and is based in Paris.
| Deal Context for Investor | # |
|---|---|
| Overall | 86 of 162 |
| Sector: Software | 3 of 6 |
| Type: Venture | 8 of 11 |
| Country: France | 70 of 119 |
| Year: 2009 | 5 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-10-01 |
Fovea Pharmaceuticals SA
Paris, France Fovea Pharmaceuticals was set up in 2005 to research and develop drugs for treating ophthalmologic disorders, such as age-related macular degeneration, retinitis pigmentosa and diabetic retinopathy. Fovea has developed a range of products in different stages of testing, from pre-clinical products to products about to undergo clinical testing. Over recent years Fovea has signed exclusive cooperation agreements with CombinatorRx Inc. and Novartis. |
Sell | €370M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-11-12 |
PanGenetics BV
Utrecht, Netherlands PanGenetics is headquartered in Utrecht, The Netherlands with an office near Cambridge in the UK. The company specialises in taking antibodies at the late research stage through to clinical proof of concept. The company employs a lean business model with most development activities outsourced, due to the wealth of specialist providers in Europe. The most advanced candidate is a CD40 antagonist that has already shown promise in an open label phase Ib/IIa Crohns study. |
Sell | - |
